Huluwa Pharmaceutical Group takes "Healthy Chinese Babies" as its corporate mission to protect the healthy growth of Chinese children and is committed to building a national brand of Chinese children's medicine. Huluwa Pharmaceutical Group is a group enterprise with Haikou as its headquarters. It was reorganized in 2008 and was listed on the main board of the Shanghai Stock Exchange in July 2020 (stock abbreviation: Huluwa, stock code: 605199).

After more than ten years of development, the group has worked hard in the field of pediatric medicine, focusing on building the entire life cycle of children and the full category of health and product industry chain, firmly following the development of pediatric medicine, and has now become one of the leading enterprises in the field of professional pediatric medicine. , and was selected as the vice chairman of the Pediatrics Branch of the Chinese Society of Traditional Chinese Medicine and the vice president of the Pediatrics Branch of the Chinese Society of Ethnic Medicine.

The group focuses on scientific and technological innovation, lean production, brand building and professional services. It has now built two major production bases in Haikou, Hainan and Nanning, Guangxi. The Haikou Mei'an Children's Medicine Intelligent Manufacturing Base will be put into production this year; a total of 34 production and sales are Children's medicines, the main products include pediatric lung heat cough and asthma granules, enteroyanning series, compound lysine granules, etc., with about 120 products under development; the sales network covers more than 2,300 counties and cities in all provinces and regions. In addition, the group has successively established academician workstations, postdoctoral research workstations, Hainan Traditional Chinese Medicine Preparation Engineering Technology Research Center, and the Joint Development Laboratory of Southern Pharmaceuticals, and jointly built an international innovation platform for high-end children's preparations research and development with well-known domestic R&D companies.

At the same time, after going public, the group has integrated various management work into ESG governance and actively assumed social responsibilities. Every year, through the children's committees of various industry societies and associations, it invested a lot of resources to ensure the safe use of medicine for children. We launched a public welfare project such as the "Spring Bree Class" that donated money to girls to enroll, and we have donated and expressed condolences to Haikou Social Welfare Institute for 7 consecutive years.

Huluwa Pharmaceutical Group insists on party building to lead the high-quality development of the enterprise, relying on the historical opportunity of the construction of Hainan Free Trade Port, continues to deepen changes with the new development concept, constantly improve product quality and craftsmanship with the spirit of craftsmanship, and wins market recognition with professional services. We will strive to become the guardian of China's children's health field, help China move from a major pharmaceutical manufacturing country to a strong pharmaceutical innovation country, and contribute the strength of the Huluwa in the new journey of promoting the great rejuvenation of the Chinese nation with Chinese-style modernization!